Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
2026-02-20 03:35:10 ET
The last time I spoke about Coherus Oncology ( CHRS ) it was with respect to a Seeking Alpha article entitled " Coherus: Biosimilar And Immuno-Oncology Pipeline Setup Could Pay Off ". With respect to this article, I noted that the company was gearing up to receive FDA approval of its anti-PD-1 monoclonal antibody LOQTORZI [toripalimab] for the treatment of patients with nasopharyngeal carcinoma. I'm happy to state that the company did indeed end up receiving approval to target both 1st-line and 2nd-line nasopharyngeal carcinoma patients. Sales of LOQTORZI have been okay, but not as good as they should be to make a difference in boosting the stock price. The company has shifted its focus towards the development of its anti-CCR8 antibody CHS-114 [tagmokitug] for several types of cancers and then the IL-27 antagonist monoclonal antibody casdozokitug for the treatment of patients with 1st-line hepatocellular carcinoma [HCC]....
Read the full article on Seeking Alpha
For further details see:
Coherus: Downgrade To 'Hold' On Potential Advancement Of Anti-CCR8 CHS-114
NASDAQ: CHRS
CHRS Trading
1.27% G/L:
$1.6507 Last:
579,941 Volume:
$1.69 Open:
